Apotex Corp.
Apotex Corp., a leading global pharmaceutical company, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1974, Apotex has established itself as a key player in the generic and specialty pharmaceuticals industry, focusing on the development, manufacturing, and distribution of high-quality medications. With a diverse portfolio that includes over 300 generic products and innovative formulations, Apotex is renowned for its commitment to affordability and accessibility in healthcare. The company has achieved significant milestones, including numerous FDA approvals and a strong presence in both the retail and hospital sectors. Apotex's dedication to quality and patient care has solidified its position as a trusted name in the pharmaceutical landscape, making it a vital contributor to global health solutions.
DitchCarbon Score
How does Apotex Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apotex Corp.'s score of 34 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apotex Corp., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company is a current subsidiary of Apotex Inc., which may influence its climate commitments and performance metrics. As of now, Apotex Corp. has not disclosed any specific emissions figures, such as Scope 1, 2, or 3 emissions, nor has it set any Science-Based Targets Initiative (SBTi) reduction targets. The absence of this data suggests that Apotex Corp. may still be in the early stages of developing its climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction commitments. However, without specific data or commitments from Apotex Corp., it is challenging to assess its current standing in relation to industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apotex Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
